文章：

一种在造血移植中选择性清除肿瘤细胞的新型高效Fas激动剂

A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants

原文发布日期：2011-12-09

DOI: 10.1038/bcj.2011.47

类型: Original Article

开放获取: 是

英文摘要：

There remains a clear need for effective tumor cell purging in autologous stem cell transplantation (ASCT) where residual malignant cells within the autograft contribute to disease relapse. Here we propose the use of a novel Fas agonist with potent pro-apoptotic activity, termed MegaFasL, as an effective ex-vivo purging agent. MegaFasL selectively kills hematological cancer cells from lymphomas and leukemias and prevents tumor development at concentrations that do not reduce the functional capacity of human hematopoietic stem/progenitor cells both in in vitro and in in vivo transplantation models. These findings highlight the potential use of MegaFasL as an ex-vivo purging agent in ASCT.

摘要翻译： 

在自体干细胞移植（ASCT）中，残留于自体移植物中的恶性细胞常导致疾病复发，因此亟需有效的肿瘤细胞清除手段。本研究提出一种新型Fas激动剂——MegaFasL，其具有强效促凋亡活性，可作为体外净化剂。MegaFasL在体外及体内移植模型中，能选择性杀伤淋巴瘤和白血病等血液系统恶性肿瘤细胞，且在不影响人造血干/祖细胞功能的浓度下，阻止肿瘤发生。这些发现凸显了MegaFasL作为ASCT体外净化剂的潜在应用价值。

原文链接：

A novel potent Fas agonist for selective depletion of tumor cells in hematopoietic transplants